We are live on ! Find out more
HALO icon

Halozyme

508 hedge funds and large institutions have $7.17B invested in Halozyme in 2024 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 179 increasing their positions, 168 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 41

82% more call options, than puts

Call options by funds: $23.1M | Put options by funds: $12.7M

12% more capital invested

Capital invested by funds: $6.4B → $7.17B (+$764M)

10% more funds holding

Funds holding: 460508 (+48)

2.8% more ownership

Funds ownership: 96.08%98.88% (+2.8%)

7% more repeat investments, than reductions

Existing positions increased: 179 | Existing positions reduced: 168

55% less funds holding in top 10

Funds holding in top 10: 115 (-6)

Holders
508
Holders Change
+48
Holders Change %
+10.43%
% of All Funds
7.28%
Holding in Top 10
5
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-54.55%
% of All Funds
0.07%
New
92
Increased
179
Reduced
168
Closed
41
Calls
$23.1M
Puts
$12.7M
Net Calls
+$10.4M
Net Calls Change
-$5.76M

HALO Hedge Fund Activity: Q3 2024 in Review

508 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q3 2024, worth a combined $7.17B — up 12% from $6.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new HALO positions and 41 closed out — a net gain of 51 holders — while 179 added to existing stakes and 168 trimmed.

The largest buyer was Congress Asset Management, adding an estimated $114M. The largest seller was TD Asset Management, cutting an estimated $46.7M.

  • 508 institutional investors held Halozyme (HALO) as of Q3 2024, up from 460 in Q2 2024.
  • Funds reported $7.17B of Halozyme stock for Q3 2024, up 12% quarter-over-quarter.
  • 92 funds opened new Halozyme positions in Q3 2024 and 41 closed out, a net change of +51 holders.
  • The largest Halozyme buyer in Q3 2024 was Congress Asset Management, an estimated $114M added.
  • The largest Halozyme seller in Q3 2024 was TD Asset Management, an estimated $46.7M sold.

Based on aggregated 13F filings for Q3 2024.